Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.48 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.45 |
| ▸ | IDO1 | P14902 | 2/20 | 0.44 |
| ▸ | MTOR | P42345 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | TDO2 | P48775 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16255667 | 0.84 | NPSR1 (0.49) | SMN1; SMN2MAPTALDH1A1HSD11B1LMNA | |
| SCHEMBL31744938 | 0.83 | HSD11B1 (0.48) | SMN1; SMN2MAPTALDH1A1HSD11B1LMNA | |
| SCHEMBL993691 | 0.81 | ALDH1A1 (0.63) | SMN1; SMN2MAPTALDH1A1LMNANPSR1 | |
| SCHEMBL12141562 | 0.81 | NPSR1 (0.46) | SMN1; SMN2ALDH1A1HSD11B1LMNANPSR1 | |
| SCHEMBL880662 | 0.81 | MAPT (0.59) | SMN1; SMN2TP53MAPTALDH1A1HTT | |
| SCHEMBL29959068 | 0.81 | MAPT (0.59) | SMN1; SMN2TP53MAPTALDH1A1HTT | |
| SCHEMBL13961606 | 0.80 | MAPT (0.62) | SMN1; SMN2TP53MAPTALDH1A1LMNA | |
| SCHEMBL1813781 | 0.80 | ALDH1A1 (0.61) | SMN1; SMN2MAPTALDH1A1LMNANPSR1 | |
| SCHEMBL78966 | 0.79 | ALDH1A1 (0.56) | SMN1; SMN2TP53MAPTALDH1A1HTT | |
| SCHEMBL16719192 | 0.78 | MAPT (0.53) | SMN1; SMN2TP53MAPTALDH1A1HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2387565-B1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS FOR TREATMENT OF INFLAMMATORY DISORDERS | RIGEL PHARMACEUTICALS INC (US) | 2016-12-14 | — | — | EP | disclosed |
| EP-2387565-B1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS FOR TREATMENT OF INFLAMMATORY DISORDERS | RIGEL PHARMACEUTICALS INC (US) | 2016-12-14 | — | — | EP | disclosed |
| US-8334297-B2 | 2,4-pyrimidinediamine compounds for treatment of inflammatory disorders | RIGEL PHARMACEUTICALS INC. (US) | 2012-12-18 | — | — | US | disclosed |
| US-8334297-B2 | 2,4-pyrimidinediamine compounds for treatment of inflammatory disorders | RIGEL PHARMACEUTICALS INC. (US) | 2012-12-18 | — | — | US | disclosed |
| US-8334297-B2 | 2,4-pyrimidinediamine compounds for treatment of inflammatory disorders | RIGEL PHARMACEUTICALS INC. (US) | 2012-12-18 | — | — | US | disclosed |
| WO-2010083241-A2 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS FOR TREATMENT OF INFLAMMATORY DISORDERS | RIGEL PHARMACEUTICALS, INC. (US) | 2010-07-22 | — | — | WO | disclosed |
| US-20100179164-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS FOR TREATMENT OF INFLAMMATORY DISORDERS | MIDCAP FINANCIAL TRUST | 2010-07-15 | — | — | US | disclosed |
| US-20100179164-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS FOR TREATMENT OF INFLAMMATORY DISORDERS | MIDCAP FINANCIAL TRUST | 2010-07-15 | — | — | US | disclosed |
| US-20100179164-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS FOR TREATMENT OF INFLAMMATORY DISORDERS | MIDCAP FINANCIAL TRUST | 2010-07-15 | — | — | US | disclosed |
| WO-2009012421-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179164-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS FOR TREATMENT OF INFLAMMATORY DISORDERS | IL2, IL1B, IL1A | SMN1; SMN2 3123/4885TP53 2812/4885MAPT 2879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.